Dr. Abbey Discusses New Treatment for Macular Telangiectasia Type 2
At AAO 2025, the American Academy of Ophthalmology’s annual meeting, Texas Retina’s Dr. Ashkan Abbey moderated a case-based roundtable discussion about the evolving landscape of macular telangiectasia (MacTel) type 2 care, including
read more
Happy Thanksgiving!
All Texas Retina Associates offices will be closed Thursday, November 27, and Friday, November 28, for the Thanksgiving holiday. During this time of reflection and gratitude, we want you to know how
read more
How Smoking Can Affect Your Eye Health
Today is the Great American Smokeout. Smoking remains the single largest cause of preventable disease and premature death in the United States. You probably know that smoking increases your risk of developing
read more
Happy Veterans Day!
On behalf of everyone at Texas Retina, we would like to extend our deepest gratitude for the sacrifices that our service members, both past and present, have made for our country.
read more
New Clinical Trials Available at Texas Retina
At Texas Retina, our physicians have participated in more than 100 national clinical trials over the past 20+ years, offering our patients access to promising new treatments for a variety of retina
read more
Texas Retina Participating in New Phase III Clinical Trial for Uveal Melanoma
Under the leadership of principal investigator Timothy Fuller, MD, Texas Retina will soon begin enrolling patients in the OptimUM-10 clinical trial, a randomized, Phase III, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic
read more
Eye Injury Prevention Month: Four Tips to Protect Your Eyes
Thousands of eye accidents happen each day, and according to the American Academy of Ophthalmology (AAO), nearly half of all eye injuries occur in the home. Did you know that wearing protective
read more Frequently Asked Questions About Eye Injections
For many retinal diseases like age-related macular degeneration, diabetic retinopathy, retinal vein occlusion and uveitis, an eye injection (also called an intravitreal injection) is the only way we can deliver potentially sight-saving medication where it is needed
read more Dr. Abbey Spoke About the VERONA Diabetic Macular Edema Clinical Trial at The Retina Society’s Annual Meeting
On behalf of the VERONA study investigators, Texas Retina’s Ashkan M. Abbey, MD, delivered a presentation titled “VERONA: End-of-Study Results from a Phase 2 Trial of EYP-1901 (vorolanib intravitreal insert) versus Aflibercept
read more
Why We Dilate Your Eyes
Patients often ask why we must dilate their eyes. A dilated retina exam is essential to properly diagnosing and monitoring a number of retina conditions, including diabetic retinopathy, macular degeneration and retinal tears or detachment. Your
read more